← Back to Analyst Consensus 
PHAT Buy
Phathom Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | initiate | — → Market Perform | — | 51% |
| Aug 17, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 31, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 31, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 30, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 17, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 27, 2026 | Barclays | upgrade | Equal-Weight → Overweight | — | 53% |
| Feb 27, 2026 | Guggenheim | maintain | Buy → Buy | $25 | 52% |
| Dec 9, 2025 | Barclays | initiate | — → Equal-Weight | $16 | 53% |
| Oct 31, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $26 | 44% |
| Jun 9, 2025 | Craig-Hallum | maintain | Buy → Buy | $17 | 54% |
| Jun 9, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Jun 6, 2025 | Needham | maintain | Buy → Buy | $28 | 50% |
| May 2, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $5 | 54% |
| May 2, 2025 | Guggenheim | maintain | Buy → Buy | $12 | 52% |
| May 2, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| May 2, 2025 | Craig-Hallum | maintain | Buy → Buy | $12 | 54% |
| Apr 21, 2025 | Needham | reiterate | Buy → Buy | $28 | 50% |
| Apr 17, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $10 | 54% |
| Apr 9, 2025 | Needham | reiterate | Buy → Buy | $28 | 50% |
| Apr 2, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Apr 2, 2025 | Needham | reiterate | Buy → Buy | $28 | 50% |
| Mar 10, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $12 | 54% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Mar 6, 2025 | Needham | reiterate | Buy → Buy | $28 | 50% |
| Jan 10, 2025 | Needham | reiterate | Buy → Buy | $28 | 50% |
| Dec 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Dec 11, 2024 | Needham | reiterate | Buy → Buy | $28 | 50% |
| Sep 13, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Sep 6, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Aug 30, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Aug 23, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Aug 19, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Aug 12, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Aug 9, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $12 | 54% |
| Jul 26, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jul 22, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jul 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $28 | 44% |
| Jul 19, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jul 12, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jul 8, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jun 28, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jun 21, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jun 14, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jun 7, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| May 31, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| May 24, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| May 17, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
| May 10, 2024 | Needham | reiterate | Buy → Buy | $26 | 50% |
Price Target Trend
Jul 2, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days